<DOC>
	<DOCNO>NCT00236769</DOCNO>
	<brief_summary>The purpose study evaluate contraceptive efficacy , safety , cycle control , compliance transdermal contraceptive system .</brief_summary>
	<brief_title>A Study Efficacy Safety With Transdermal Contraceptive System .</brief_title>
	<detailed_description>This open-label , multicenter , global study evaluate contraceptive efficacy , cycle control , safety , compliance subject satisfaction transdermal contraceptive system . Sixteen hundred healthy woman wear contraceptive patch either 6 13 cycle . The first 530 subject wear patch 13 cycle , subsequent subject wear patch 6 cycle . At admission Visit 1 , study drug ( plus 3 reserve patch ) diary card dispense Cycle 1 ; first patch application first day menses . Study drug diary card dispense day 28 Cycle 1 ( Visit 2 ) Cycles 2 3 , day 28 Cycle 3 ( Visit 3 ) Cycles 4 6 , day 28 Cycle 6 ( Visit 4 ) Cycles 7 9 , day 28 Cycle 9 ( Visit 5 ) Cycles10 to13 . At visit , diary card empty medication package collect . Final study visit day 28 Cycles 6 13 . Diary card information use record compliance bleed information ( assess cycle control ) . Contraceptive efficacy assess mean Pearl Index life table analysis ( gross cumulative probability pregnancy ) . Safety evaluation base adverse event , collect throughout study , change gynecologic examination , vital sign , laboratory result admission final visit . Each transdermal contraceptive patch , contain 6 mg NGM 0.75 mg EE , deliver 250 ug 17-dNGM 25 ug EE 24 hour 7 day , worn 1 week replace 3 consecutive week . The fourth week patch-free . The patch worn : upper arm torso , buttock , abdomen .</detailed_description>
	<mesh_term>Norelgestromin</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<criteria>Healthy woman regular menstrual cycle sexually active risk pregnancy nonpregnant acceptable body mass index ( BMI ) last term pregnancy least 42 day prior , nonlactating , 1 normal menstrual cycle since sit BP &lt; 140mmHg/ &lt; 90mmHg 1 normal menstrual cycle since removal IUD norplant agreement use study drug contraception 13 cycle , except backup contraception require disease protection patch detachment agree use systemic steroid medication Presence , history , hereditary predisposition risk deep vein thrombophlebitis thromboembolic disorder cerebral vascular coronary artery disease , hypertension , severe migraine liver tumor result estrogencontaining product diabetes mellitus cholestatic jaundice , liver renal disease abnormal PAP smear thyroid disorder dermal hypersensitivity carcinoma breast , endometrium estrogendependent neoplasia substance abuse receive experimental drug within prior 30 day smoke woman 35 year age .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>contraception</keyword>
	<keyword>transdermal contraception</keyword>
	<keyword>hormonal , steroidal contraception</keyword>
	<keyword>ethinyl estradiol</keyword>
	<keyword>progesterone</keyword>
</DOC>